• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Sunday, August 3, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Immunology

Scientists develop better way to block viruses that cause childhood respiratory infections

Bioengineer by Bioengineer
May 10, 2021
in Immunology
Reading Time: 4 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

IMAGE

Credit: Images by Victor Outlaw.

MADISON – By engineering a short chunk of protein, or peptide, that can prevent the attachment of human parainfluenza viruses to cells, researchers have improved a method in rodent models intended to help keep children healthy.

Human parainfluenza viruses, or HPIVs, are the leading cause of childhood respiratory infections, responsible for 30% to 40% of illnesses like croup and pneumonia. The viruses also affect the elderly and people with compromised immune systems.

To sicken people, HPIVs must latch onto cells and inject their genetic material to start making new viruses. HPIV3 is the most prevalent among these viruses. There are currently no approved vaccines or antivirals for HPIV3 infection in people.

In a study led by the Sam Gellman lab in the chemistry department at the University of Wisconsin-Madison, and the lab of Anne Moscona and Matteo Porotto at Columbia University, researchers built upon years of work on peptide treatments to generate one capable of blocking the HPIV3 attachment process.

The researchers published their findings April 7 in the Journal of the American Chemical Society.

To enter host cells, HPIVs use specialized fusion proteins that resemble three corkscrews laid side-by-side. Earlier work by the Moscona-Porotto lab showed that scientists could a partial chunk of this corkscrew protein from HPIV3, introduce this peptide to the virus, and prevent the corkscrew from driving the infection process. The peptide, itself a corkscrew, essentially zippers up with the virus’s corkscrews, creating a tight bundle of six corkscrew shapes.

The new peptide persists longer in the body, making it about three times more effective at blocking infection in rodent models of disease than the original form.

The research team started by trying to engineer the original peptide to be more resistant to protein-digesting enzymes in the body, which can easily shred proteins and make them useless. So, the Gellman lab turned to unusual building blocks to create a hardier peptide.

Cells build proteins out of alpha amino acids. But chemists can create beta amino acids, which are similar but have an extra carbon atom. When peptides use these beta amino acid building blocks, they often take a different shape because of the extra atom. This can help a peptide hide from protein-digesting enzymes and survive longer.

However, the researchers also knew that if the peptide’s shape changed too much as a result of these unusual building blocks, they might not lock together with HPIV’s corkscrew fusion protein.

That’s where the Gellman lab’s decades of experience testing and modifying beta amino acid-containing peptides became critical.

“We know which side of the peptide is binding to its protein target. So, we (knew that we) can modify only residues that are not directly involved in binding the viral protein,” says Victor Outlaw, a postdoctoral researcher in the lab and one of the co-first authors of the report. In lab tests, they saw that the carefully modified peptide still bound strongly to the virus’s protein.

In another improvement pioneered by the Moscona-Porotto lab, the scientists hooked the peptide up to a molecule of cholesterol. This fatty addition helps the peptide slide into the greasy cell membrane, where it can best block the virus.

“Our hypothesis was that the combination of beta amino acids and cholesterol would increase anti-viral efficacy,” says Outlaw, who explained that the cholesterol helped get the peptide to where it needed to go, while the shape change from the beta amino acids allowed the peptide to persist longer in the body.

As the research team hoped, when they gave the new peptide to cotton rats it lasted much longer in the lungs than the previous version did thanks to its resistance to digestion by enzymes. The peptide was delivered into the rats’ noses.

To test how well the peptide worked to prevent infection, cotton rats received the new peptide before they were exposed to HPIV3. Compared to animals given no antiviral peptides, those given the improved peptide had 10 times fewer viruses in their lungs.

And compared to the peptide that was more susceptible to enzymes, the hardier peptide reduced viral load by about three times, suggesting that the new peptide’s ability to avoid digestion in the body helps it better block infection.

While the approach hasn’t yet been tested in humans and researchers must further refine and test the system, it does provide a new strategy for potentially preventing or treating these common infections.

The research collaboration is now looking to make second-generation peptides that last even longer in the body. They also want to test how well the modified peptide might block infection by related viruses. That additional research could move the peptide treatment closer to clinical trials.

“This was a very fortunate coming together of groups that had complementary needs and capabilities,” says Gellman. “It’s really been a great joint effort.”

###

This work was supported by the National Institutes of Health (grants R01AI114736, R01 GM056414, F32 GM122263 and T32 GM008349.)

–Eric Hamilton, (608) 263-1986, [email protected]

Media Contact
Sam Gellman
[email protected]

Original Source

https://news.wisc.edu/scientists-develop-better-way-to-block-viruses-that-cause-childhood-respiratory-infections/

Related Journal Article

http://dx.doi.org/10.1021/jacs.1c01565

Tags: Chemistry/Physics/Materials SciencesImmunology/Allergies/AsthmaInfectious/Emerging DiseasesVaccinesVirology
Share12Tweet8Share2ShareShareShare2

Related Posts

IMAGE

UMass Amherst grad student awarded fellowship for food allergy research

July 23, 2021
IMAGE

Less-sensitive COVID-19 tests may still achieve optimal results if enough people tested

July 22, 2021

Public trust in CDC, FDA, and Fauci holds steady, survey shows

July 20, 2021

USC study shows male-female differences in immune cell function

July 19, 2021
Please login to join discussion

POPULAR NEWS

  • Blind to the Burn

    Overlooked Dangers: Debunking Common Myths About Skin Cancer Risk in the U.S.

    60 shares
    Share 24 Tweet 15
  • Neuropsychiatric Risks Linked to COVID-19 Revealed

    48 shares
    Share 19 Tweet 12
  • Dr. Miriam Merad Honored with French Knighthood for Groundbreaking Contributions to Science and Medicine

    46 shares
    Share 18 Tweet 12
  • Study Reveals Beta-HPV Directly Causes Skin Cancer in Immunocompromised Individuals

    38 shares
    Share 15 Tweet 10

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Rigid Crosslinker Enables Nondestructive Patterned QLEDs

Predicting Hidden Cervical Cancer via Cytology, ECC

High-Capacity Phase-Sensitive Amplification In Fiber

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.